A Biotech ETF For Aggressive, Risk-Tolerant Investors

A Biotech ETF For Aggressive, Risk-Tolerant Investors

The biotechnology sector has been on fire thanks to news from Biogen Inc. BIIB. The FDA approved its controversial drug that can treat Alzheimer’s Disease.

Not surprisingly, there have been big moves by many of the stocks in this sector. Aggressive investors have been buying the Direxion Daily S&P Biotech Bull 3X Shares ETF LABU.

This ETF seeks the daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Index for a single day.

If the index continues to move higher, LABU should move by about three times as much. But it goes the other way, too, and investors need to exercise caution. If the index heads south, LABU will fall by about three times as much.

(Click on image to enlarge)

labu.png

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with